Serial entrepreneur. Since 2010, he has been involved in the management of three companies in the biotechnology industry. He served as the founding CEO of two of these companies (Cyfuse Biomedical (TSE: 4892) and EXORPHIA) and as a Director and Executive Officer at the other (ReproCell (TSE:4978)). He founded EXORPHIA in May 2019 and assumed the position of President and CEO (current). He possesses extensive experience in founding and managing R&D-focused ventures.
Prior to the biotech industry, he engaged in the development of mobile devices at Panasonic, patent application work at a patent law firm, and formulating management strategies and operational reforms for manufacturing industries at McKinsey & Company. He graduated from Keio University, Faculty of Science and Technology.

After serving as a partner at Hasegawa Toshiaki Law Office and Squire Sanders Foreign Law Joint Enterprise (currently Squire Foreign Law Joint Enterprise), he established Matsumoto Munehiro Law Office in 2013, where he currently serves as the representative attorney. He graduated from the Faculty of Law at the University of Tokyo and received his LL.M. from the University of Pennsylvania Law School in the United States.

He engaged in consulting for the pharmaceutical and medical device sectors at McKinsey & Company. He was a postdoctoral fellow at the Institute for Integrated Cell-Material Sciences (iCeMS) at Kyoto University. He obtained his Ph.D. in stem cell biology and molecular biology from the Institute of Molecular and Cellular Biosciences at the University of Tokyo.

He was engaged in management consulting for domestic and foreign companies at EY Strategy and Consulting Co., Ltd.
Throughout his career, he has tackled various management issues such as management strategy, new business planning, R&D strategy, and M&A, mainly for pharmaceutical companies, medical device companies, and healthcare companies such as medical institutions.
In 2021, Satake joined KII as a venture capitalist specializing in the medical healthcare field.
He graduated from the School of Pharmaceutical Sciences at Osaka University and the Graduate School of Pharmaceutical Sciences at The University of Tokyo.

At Ohta Showa Audit Corporation (currently Ernst & Young ShinNihon LLC), he was in charge of auditing major chemical manufacturers and supported numerous IPOs. After working on supporting the growth of university-based ventures, he became independent in July 2019 and established EDiX Professional Group Edogawa CPA Office, where he currently serves as the representative partner. He graduated from the Faculty of Law, Department of Law, at Keio University.